NEJM 26 Jan 2017 Vol 376 Bezlotoxumab Bezlotoxumab is an antibody that offers passive protection against Clostridium difficile toxin. This trial shows that if you give it with anti-clostridial antibiotics, it somewhat lowers the rate of recurrence. It is already on sale in the US, though in that strange country, drug prices are commercial secrets. […]
Richard Lehman’s journal review—30 January 2017
